- Details
- Jindan Yu delves into her team's research on "Chemokine Receptor CXCR7 Activates Aurora Kinase A and Promotes Neuroendocrine Prostate Cancer Growth," published in the Journal of Clinical Investigation. Dr. Yu's study began with the observation that CXCR7, an atypical chemokine receptor, is upregulated in enzalutamide-resistant prostate cancer cells. The research reveals that CXCR7, unlike the bett...
|
- Details
- Andrew Goldstein discusses his group's publication in Cell Reports, focusing on the role of MYC in metabolic changes induced by androgen receptor (AR) inhibition in prostate cancer. The study, led by graduate students Preston Crowell and Jenna Giafaglione, explores how prostate cancer cells initially respond to AR inhibition treatments. Utilizing clinical datasets, metabolic profiling, and nutrien...
|
- Details
- Sarah Amend delves into her research on Polyaneuploid Cancer Cells (PACCs) and their increased metastatic potential, a study published in Clinical and Experimental Metastasis. Dr. Amend, a recipient of the 2023 Challenge Award, led by graduate student Mikaela Mallin, explores the response of prostate cancer cells to cisplatin, revealing significant morphological changes and increased cell size, in...
|
- Details
- Ruchika Talwar hosts Avery Braun to discuss a study that investigates the relationship between anticholinergic medications and the onset of dementia in prostate cancer patients. Dr. Braun explains that the research focuses on men living decades after prostate cancer treatment, who often use PDE5 inhibitors or anticholinergics for erectile dysfunction or overactive bladder. The study, utilizing the...
|
- Details
- Steven Patierno delves into his 25-year journey tackling cancer disparities, with a focus on prostate cancer. Beginning in Washington D.C., Dr. Patierno's work highlighted the stark impact of socioeconomic factors and healthcare access on cancer care. At Duke, he leads a comprehensive approach addressing the intricate mix of social inequities, healthcare access, and ancestry-related biology. He em...
|
- Details
- Alicia Morgans interviews Gerhardt Attard about groundbreaking research presented at ESMO 2023, utilizing the STAMPEDE data set. They discuss a new prognostic tool developed with Artera, the ArteraAI Prostate Score, which predicts prostate cancer-specific mortality using digitized images of H&E slides from over 3,300 patients. This tool has proven that primary tumor analysis can provide significan...
|
- Details
- Tamara Lotan delves into the evolution of pathology in the realm of urologic oncology, emphasizing the integration of digital and AI technologies. Dr. Lotan highlights how digital pathology, particularly in prostate cancer diagnosis and grading, significantly augments traditional methods. She discusses the potential of AI in creating novel prognostic models that could improve upon the established...
|
- Details
- Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...
|
- Details
- Daniel Spratt explains advances in radiation oncology for prostate cancer, explaining how techniques have evolved from whole pelvis radiation with high toxicity to conformal therapies like SBRT that precisely target the prostate and dramatically reduce side effects. He discusses research on further hypofractionation with as few as 1-2 treatments, ongoing trials of focal therapy boosting dominant n...
|
- Details
- Daniel Spratt discusses how radiation therapy is expanding its role in prostate cancer treatment through techniques like dose painting and as adjuvant therapy with systemic treatments. He presents research showing how AI and biomarkers can help personalize radiation and hormone therapy to avoid over-treatment. Dr. Spratt sees radiation therapy continuing to evolve with more convenient hypofraction...
|
